Back to top
more

G1 Therapeutics (GTHX)

(Delayed Data from NSDQ)

$4.55 USD

4.55
502,403

+0.02 (0.44%)

Updated May 20, 2024 04:00 PM ET

After-Market: $4.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GTHX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

G1 Therapeutics [GTHX]

Reports for Purchase

Showing records 81 - 100 ( 350 total )

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 81

07/29/2022

Company Report

Pages: 7

Model Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 82

07/25/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 83

07/25/2022

Company Report

Pages: 5

Our Updated COSELA Revenue Estimates Ahead of the Q2 Report

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 84

07/13/2022

Daily Note

Pages: 3

Cosela Receives Approval in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in ES-SCLC Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 85

06/13/2022

Daily Note

Pages: 3

Complete Enrollment Announced In Phase 3 PRESERVE 1 Trial of Cosela in mCRC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 86

06/03/2022

Company Report

Pages: 8

Cosela For ES-SCLC Post-Hoc Analysis Data Presented at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 87

06/02/2022

Daily Note

Pages: 5

Trilaciclib Suppresses Myelosuppression at ASCO

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 88

05/31/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 89

05/29/2022

Industry Report

Pages: 17

2022 Abstract Roundup For Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 90

05/27/2022

Industry Report

Pages: 8

ASCO 2022 Abstracts Released

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 91

05/23/2022

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 92

05/23/2022

Daily Note

Pages: 4

KOL Webinar: A Clinical Perspective of Using COSELA in the Treatment of Cancer Patients

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 93

05/19/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 94

05/19/2022

Company Report

Pages: 5

KOL Webinar Wednesday, May 25, 2022 at 12:00 pm ET with Dr. Jared Weiss

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 95

05/05/2022

Company Report

Pages: 8

1Q22 Results; Strong Cosela Sales Growth With G1''s Fully Deployed Sales Team; Data From 3 Phase 2 Trials Expected 4Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 96

05/04/2022

Company Report

Pages: 7

Cosela Primed for a Year of Commercial Execution; and Data

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 97

05/04/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 98

05/04/2022

Company Report

Pages: 6

1Q22: Sequential COSELA Revenue Growth. PT $33.

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 99

04/27/2022

Company Report

Pages: 8

Highlights From Non-Deal Roadshow

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Company: G1 Therapeutics

Industry: Medical - Biomedical and Genetics

Record: 100

04/01/2022

Company Report

Pages: 8

New Data Support Cosela Potential in Reducing Myelosuppression Due to Chemotherapy in Patients with ES-SCLC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party